

# Advance HTA

Rethinking the future of Health Technology Assessment

[www.advance-hta.eu](http://www.advance-hta.eu)

**WP7 - Potential implications: lessons learnt, policy recommendations and advances in HTA**

**The fundamental objective is to contribute to advancements in the methods for HTA in European and other settings by involving the wider stakeholder community in areas actively and heavily debated given their implications for decision-making and resource allocation**

## WP1 Value for Money

**Aim:** To determine empirically the main factors driving HTA decisions across 10 EU countries.

### Deliverables

- ✓ **Taxonomy of methods & survey** on the assessment of value in EU Member States
- ✓ **Valuation of health gains** and refinement of benefit measures for value-based pricing

## WP4 Quality of Life

**Aim:** To determine whether the preferences towards HRQoL differ between the general population and defined patient groups, and define the policy implication of using value sets drawn from specific patient populations

### Deliverables

- ✓ **Primary data collection** of patient HRQoL data and database establishment
- ✓ **Newly defined value sets** and their policy implications

## WP2 Value Assessment

**Aim:** To understand the parameters of value in HTA appraisals from an international perspective, explore how other factors can be incorporated and how alternative frameworks such as MCDA can be used to elicit value

### Deliverables

- ✓ **Systematic review of value assessment** methodologies
- ✓ Develop a new methodological framework for value assessment based on **Multiple Criteria Decision Analysis (MCDA)**

## WP5 Medical Devices

**Aim:** To map the methodology and process of HTA and how it is used in appraising medical devices in EU, and to identify how the current assessment tools can be modified with a view to producing robust HTA methods

### Deliverables

- ✓ **Taxonomy of existing classifications and nomenclatures** of medical devices
- ✓ **Survey results of HTA tools** and synthesis report on HTA advances in medical devices

## WP3 Rare Diseases & Orphan Drugs

**Aim:** To understand the impact that rarity has on the incremental cost/QALY and to develop a framework to support decision making relating to orphan drugs for rare diseases through a DCE survey

### Deliverables

- ✓ **Systematic analysis of 20 drugs** to identify value assessment criteria of orphan drugs
- ✓ Socio-economic costs and HRQoL of rare disease patients through a **Discrete Choice Experiment (DCE)** survey to derive utilities, followed by case studies

## WP6 Emerging Settings

**Aim:** To identify the use and capacity for using HTA in emerging settings and to encourage its use for decision making through the development of formal guidelines in the context of Emerging Countries

### Deliverables

- ✓ **Mapping of HTA capacity in Eastern Europe and Latin America**, tool box on best practice and recommendations
- ✓ **Recommendations on HTA** strengthening and implementation in emerging settings

## WP8

**Dissemination of objectives and results**  
Workshops with regional decision-makers:  
Warsaw - Poland, September 2014  
Mexico City - Mexico, November 2014

## WP9

**Coordination and Management**

**Partners** London School of Economics and Political Science, UK (**Coordinator**); London School of Hygiene and Tropical Medicine, UK; University Castilla- La Mancha, Faculty of Health Science, Spain; Institute for Economic Research, Slovenia; Technische Universität Berlin, Germany; Andalusian School of Public Health, Spain; Pan-American Health Organisation, USA; European Brain Council, Belgium; University Paris Est Créteil, France; National Institute for Health and Clinical Excellence International, United Kingdom; Health Technology Assessment Agency, Poland; Dental and Pharmaceutical Benefits Board, Sweden

**Scientific Advisory Board** Prof. David Taylor (Chair, UCL), Prof Lise Rochaix (CEESP), Dr. Karen Facey (HTAI Policy Forum), Dr. Finn Borlum Kristenson (EUnetHTA), Dr Josep Figueras (European Observatory)